Corcept Therapeutics Incorporated (FRA:HTD)
68.14
+0.22 (0.32%)
At close: Nov 28, 2025
Corcept Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 741.17 | 675.04 | 482.38 | 401.86 | 365.98 | 353.87 | Upgrade | |
Revenue Growth (YoY) | 17.92% | 39.94% | 20.04% | 9.80% | 3.42% | 15.46% | Upgrade |
Cost of Revenue | 13.39 | 10.88 | 6.48 | 5.39 | 5.28 | 5.58 | Upgrade |
Gross Profit | 727.78 | 664.16 | 475.89 | 396.47 | 360.7 | 348.29 | Upgrade |
Selling, General & Admin | 401.86 | 280.32 | 184.26 | 152.85 | 122.36 | 105.33 | Upgrade |
Research & Development | 260.35 | 246.89 | 184.35 | 130.99 | 113.86 | 114.76 | Upgrade |
Operating Expenses | 662.21 | 527.21 | 368.61 | 283.84 | 236.22 | 220.09 | Upgrade |
Operating Income | 65.57 | 136.95 | 107.28 | 112.63 | 124.48 | 128.2 | Upgrade |
Interest & Investment Income | 22.94 | 24.54 | 17.28 | 3.56 | 0.53 | 3.4 | Upgrade |
Legal Settlements | - | - | - | -14 | - | - | Upgrade |
Pretax Income | 88.51 | 161.49 | 124.56 | 116.19 | 125.01 | 131.6 | Upgrade |
Income Tax Expense | -17.6 | 20.28 | 18.42 | 14.77 | 12.49 | 25.59 | Upgrade |
Net Income | 106.11 | 141.21 | 106.14 | 101.42 | 112.51 | 106.01 | Upgrade |
Preferred Dividends & Other Adjustments | 1.45 | 1.48 | 0.64 | 0.13 | - | - | Upgrade |
Net Income to Common | 104.66 | 139.73 | 105.5 | 101.29 | 112.51 | 106.01 | Upgrade |
Net Income Growth | -25.18% | 33.04% | 4.66% | -9.86% | 6.13% | 12.56% | Upgrade |
Shares Outstanding (Basic) | 104 | 103 | 104 | 107 | 116 | 115 | Upgrade |
Shares Outstanding (Diluted) | 120 | 113 | 112 | 116 | 126 | 124 | Upgrade |
Shares Change (YoY) | 7.55% | 1.55% | -3.64% | -7.94% | 1.42% | 1.33% | Upgrade |
EPS (Basic) | 1.01 | 1.35 | 1.02 | 0.95 | 0.97 | 0.92 | Upgrade |
EPS (Diluted) | 0.87 | 1.23 | 0.94 | 0.87 | 0.89 | 0.85 | Upgrade |
EPS Growth | -30.72% | 30.85% | 8.05% | -2.25% | 4.71% | 10.39% | Upgrade |
Free Cash Flow | 163.1 | 195.9 | 126.9 | 119.91 | 167.42 | 150.73 | Upgrade |
Free Cash Flow Per Share | 1.36 | 1.73 | 1.14 | 1.03 | 1.33 | 1.21 | Upgrade |
Gross Margin | 98.19% | 98.39% | 98.66% | 98.66% | 98.56% | 98.42% | Upgrade |
Operating Margin | 8.85% | 20.29% | 22.24% | 28.03% | 34.01% | 36.23% | Upgrade |
Profit Margin | 14.12% | 20.70% | 21.87% | 25.20% | 30.74% | 29.96% | Upgrade |
Free Cash Flow Margin | 22.00% | 29.02% | 26.31% | 29.84% | 45.75% | 42.59% | Upgrade |
EBITDA | 66.71 | 137.75 | 108.32 | 113.89 | 125.96 | 128.73 | Upgrade |
EBITDA Margin | 9.00% | 20.41% | 22.46% | 28.34% | 34.42% | 36.38% | Upgrade |
D&A For EBITDA | 1.14 | 0.8 | 1.04 | 1.26 | 1.48 | 0.53 | Upgrade |
EBIT | 65.57 | 136.95 | 107.28 | 112.63 | 124.48 | 128.2 | Upgrade |
EBIT Margin | 8.85% | 20.29% | 22.24% | 28.03% | 34.01% | 36.23% | Upgrade |
Effective Tax Rate | - | 12.56% | 14.79% | 12.71% | 9.99% | 19.45% | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.